Clinical implications of targeting VEGF in solid tumors.
Conventional chemotherapy does not improve overall response rates in many patients with metastatic disease. Vascular endothelial growth factor (VEGF) has been identified as a target for novel therapeutics designed to inhibit tumor angiogenesis, which is essential for tumor growth and metastasis. This session provided nurses with information about the potential clinical implications of VEGFs, including proper administration, patient education, and side-effect management.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D024802:Nurse's Role; D009859:Oncology Nursing / Q000379:methods*; D015996:Survival Rate; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A